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 Abstract 
 
Objective: The objective of this systematic review is to determine whether growth hormone is an 
effective adjunct in the treatment of obesity for promoting fat loss while retaining lean body 
mass. 
Study Design: This is a systematic review of studies performed measuring the effects of growth 
hormone as adjunct treatment to standard regimens including bariatric surgery, severe calorie 
restriction, and lifestyle modifications. 
Data Sources: The data sources included an open prospective RCT analyzing GH as adjunct to 
LASGB (Savastano,2009), a single blind placebo controlled study analyzing GH as adjunct to 
severe calorie restriction (Tagliaferri,1998), and randomized double blind placebo controlled trial 
analyzing GH as adjunct to lifestyle modifications (Albert,2004).  
Outcomes Measured: These included percent fat mass (FM%), fat mass percent change, fat mass 
(kg), lean body mass percent (LBM%), lean body mass (kg), lean body mass percent change, and 
weight decrement (kg).  
Results: The results of this review showed that in all cases, fat mass loss was greater in the 
groups treated with growth hormone, while lean body mass retention was also greater in the 
growth hormone treated groups. The degree to which the growth hormone treated groups showed 
statistically significant improvements over the placebo group varied depending on the standard 
treatment regimen, as well as the time period of observation. 
Conclusion: Growth hormone is an effective adjunct to standard treatment regimens for 
promoting fat mass loss and retaining lean body mass in the management of obesity. 
Keywords: obesity, growth hormone, bariatric surgery 
 
 Introduction 
 More common in western industrialized nations, obesity is one of the most common 
conditions encountered by medical professionals, effecting people of all ages, races, and genders. 
Clinically defined as a body mass index greater than 30 (BMI: kg/m
2
), obesity effects nearly one 
in three people in the U.S, although rates amongst those in a lower socioeconomic class and 
lower education levels are even higher. In a 2008 study, the age-adjusted prevalence of obesity 
was 33.8% (95% CI, 31.6%-36.0%) overall, 32.2% (95% CI, 29.5%-35.0%) among men, and 
35.5% (95% CI, 33.2%-37.7%) among women 
1
.  
 The importance of recognizing and treating obesity can be seen in its prevalence as a 
major risk factor or exacerbating factor for many of the most common medical conditions, 
including many types of cancer, depression, ischemic heart disease, diabetes mellitus type 2, 
asthma, hypertension, osteoarthritis, low back pain, and GERD.  Another important measurement 
of the impact of obesity is seen in the financial impact that it has on overall medical costs. In 
2008, obesity accounted for 9.1% of all medical spending in the U.S., up from 6.5% in 1998. 
Overall, an obese patient had $4,871 in medical bills per year, compared with $3,442 for a non 
obese patient
1
. Although these statistics are easily understood and observed by most medical 
professionals in practice, they are likely understated and the full impact of obesity on health and 
the healthcare system is underestimated and not fully understood.  
Another difficulty in the management of obesity is the lack of knowledge about an 
optimal strategy to treat obesity. Some of the more common methods include lifestyle 
modifications such as diet and exercise, calorie restriction, surgery, and pharmaceuticals 
designed to aid in weight loss. Recent studies have shown that many obese subjects also suffer 
 from functional growth hormone deficiency. A substantial body of evidence supports the theory 
that neuroregulation of secretion of GH by the pituitary is closely related to the amount of 
adipose tissue in the body. This relationship between adipose tissue stores and GH is part of a 
regulation of feeding and fasting, with the purpose of maintaining proper body weight and body 
composition. Specifically, those with higher levels of adipose tissue tend to have lower levels of 
GH secretion, a condition that seems to be reversible upon normalization of body adipose tissue 
stores
3
. This paper evaluates three studies comparing standard treatment regimens alone versus 
growth hormone as an adjunct to those treatment regimens. The reason for the addition of growth 
hormone to a standard treatment regimen is based on the fact that maintenance of lean body mass 
(LBM) is of great importance in maintaining metabolism and function during the treatment of 
obesity. The goal of any treatment regimen should be to lose fat body mass (FBM) while 
maintaining LBM.  
Objective 
 The goal of this review is to determine if growth hormone (GH) is a safe and effective 
adjunct treatment to standard regimens in the management of obesity. The hypothesis is that 
weight loss strategies are more successful at decreasing FBM and retaining LBM with growth 
hormone as an adjunct to the standard treatment regimen. 
Methods 
 The studies located were RCT’s that involved populations undergoing treatment for 
obesity, as well as a set of that population receiving GH as an adjunct to the standard treatment 
regimen. The standard treatment regimens included lifestyle modifications, Laparoscopic 
Adjustable Gastric Banding (LASGB), and calorie restriction. Comparison was done of the 
 outcomes of those receiving the standard treatment, versus those receiving GH in addition to the 
standard treatment. Outcomes measured included FBM loss, %FBM loss, LBM retained, %LBM 
retained, and weight loss. The types of studies used included randomized double blind study, 
single blind placebo controlled study, and an open label prospective randomized controlled 
study. PubMed and Cochrane databases were used to gather information. Criteria used for the 
selection of these studies included 1) literature published in English between 1996-present, 2) 
Studies chosen all dealt with POEMS, 3) Studies being used for statistical analysis were RCT’s, 
4) Studies being analyzed had not been previously used in a meta analysis or systematic review, 
5) RCT studies used showed statistical significance for results (p<0.05). Any studies not 
adhering to these criteria were not used. Choosing the English language and studies on Humans 
only, and using the keywords: “growth hormone”, “obesity”, and “bariatric surgery”, the search 
was narrowly focused as to avoid unnecessary or irrelevant studies that did not include POEMS 
that were not applicable. From these searches of the databases, 3 studies were procured that were 
used to derive scientific data with statistical analysis. These studies were: 1) Open prospective 
randomized controlled trial, comparing LASGB alone versus LASGB in addition to growth 
hormone (GH) in the treatment of obesity. 2) Single blind placebo controlled study, comparing 
calorie restriction regimen versus calorie restriction in addition to GH in the treatment of obesity. 
3) Randomized double blind placebo controlled trial, comparing lifestyle modification alone 
versus GH in addition to lifestyle modification in the treatment of obesity.  
 Outcomes measured in the studies had to be POEMS, such as body weight lost, weight 
loss due to body fat loss, and lean body mass retained. To help measure these outcomes, in 
addition to conventional methods of measuring weight, dual energy x-ray absorptiometry scan 
(DEXA) was used to measure body composition.    
 Results 
The major characteristics of the trials used in this study are displayed in Table 1.  
Although inclusion and exclusion criteria varied to some degree amongst the studies, patients 
from all three studies underwent similar assessments for obesity.  
Table 2 shows the comparison of Growth Hormone (GH) as an adjunct to bariatric 
surgery, specifically Laparoscopic Adjustable Silicone Gastric Banding (LASGB), versus 
LASGB alone. The major outcomes analyzed in this study were fat mass percentage (FM%), fat 
mass percentage change, lean body mass percentage (LBM%), lean body mass percentage 
change, and weight decrement. These outcomes were measured at the initiation of the study, 
after three months, and again after six months, by conventional measures of body weight, as well 
as dual energy x-ray absorptiometry (DEXA) to analyze body composition and differentiate 
between fat tissue and lean body tissue. The results were as follows: Fat mass percentage (FM%) 
and Lean Body Mass percentage(LBM%) were measured for both the control group and growth 
hormone group and were roughly equal at baseline for both groups.  At 3 and 6 months, the GH 
group showed a significant decline in FM% as well as a significant increase in LBM%. P values 
for the GH group showed statistical significance. The control group did not show similar results. 
In this group, FM% actually increased at the 3 month period, while LBM% decreased. At 6 
months however, both FM% and LBM% returned to levels near baseline. The data for the 
control group did not have a p-value that demonstrated statistical significance. Fat mass 
percentage change was also reported in this study, and the GH group once again showed 
significant results, declining by 7.3 +/- 8.0% at 3 months and 20.7 +/- 9.3% at 6 months. The  
 control group saw a moderate increase in FM% change at 3 months of +8.6 +/- 9.2% and 
returned to levels near baseline at 6 months. Another important value reported in this study was 
weight decrement. For the GH group, weight declined by 10.7 +/- 4.2 kg at 3 months, and 15.2 
+/- 5.7 kg at 6 months, while the control group saw a decline of 12.0 +/- 7.9 kg at 3 months and 
21.3 +/- 8.0 kg at 6 months. P values for these data showed significance for both groups. At first 
glance it would appear that the control group showed a more significant effect on weight loss 
than the GH group, but after considering that lean body tissue weighs more than fat tissue, it is  
understood that subjects who retained more LBM maintained a higher weight. 
Table 2. Comparison of Body Composition and Weight Changes in GH as Adjunct to LASGB vs 
LASGB alone 
FM= Fat Mass, LBM= Lean Body Mass 
1 Authors report the amount of fat mass lost in Group A at 3 and 6 months was more 
statistically significant compared to Group B 
2 Authors report that % LBM retained in Group A at 3 and 6 months was more statistically 
significant compared to Group B 
 Group A 
(GH treated) 
n=12 
Group B 
(Not GH treated) 
n=11 
 Baseline 3 
months 
6 
months 
P value Baseline 3 
months 
6 
months 
P value 
FM% 47.2 +/- 
4.9 
43.7 +/- 
4.6 
37.6 +/- 
4.2 
0.005 47.5 +/- 
4.5 
51.2 +/- 
3.7 
47.6 +/- 
5.2 
0.103 
FM%  
change 
 -7.3 +/- 
8.0 
-20.7 +/- 
9.3 
0.0011  8.6 +/- 
9.2 
0.8 +/- 
13.7 
0.014 
LBM%  52.7 +/- 
4.9 
56.3 +/- 
4.6 
63.1 +/- 
7.2 
0.005 52.5 +/- 
4.7 
48.7 +/- 
3.7 
54.7 +/- 
7.2 
0.061 
LBM  
change (kg) 
 -2.8 +/- 
3.8 
2.6 +/- 
4.1 
0.004  -12.0 +/- 
5.9 
0.4 +/- 
6.5 
<0.0001 
LBM %  
change 
 7.2 +/- 
8.0 
18.2 +/- 
7.9 
0.0022  -6.8 +/- 
8.6 
4.1 +/- 
8.3  
0.024 
Weight 
Decrement 
(kg) 
 -10.7 +/- 
4.2 
-15.2 +/- 
5.7 
0.005  -12.0 +/- 
7.9 
-21.3 +/- 
8.0 
0.006 
 
 Table 3 shows the comparison of GH as an adjunct to severe calorie restriction in obese 
women versus calorie restriction alone. The outcomes measured in this study were body weight, 
BMI (kg/m
2
), fat mass, lean body mass, and percent lean body mass loss. These outcomes were 
measured at the beginning of the study, and after four weeks. Conventional measures were used 
to calculate weight, and DEXA scan was used to analyze body composition and determine fat 
mass and lean body mass. The results of this study showed Body Weight and BMI were roughly 
equal for both the GH group and placebo group at baseline and 4 weeks, as both showed a 
moderate decline over the 4 week period. Fat mass also showed similar declines in both groups, 
from 49.07 +/- 2.10 to 43.71 +/- 2.42 in the GH group, and 47.02 +/- 1.44 to 42.73 +/- 1.66 in the 
placebo group. The most notable difference between the two groups was seen in the maintenance 
of Lean Mass. The placebo group showed a decline from 43.83 +/- 1.15 to 40.04 +/- 1.14 kg, a 
decrease of 8.6 +/- 1.01%. The GH group showed a decline from 42.14 +/- 1.42 to 40.61 +/- 1.29 
kg, a decrease of only 3.5 +/- 1.39%.  
Table 3. Comparison of GH in Addition to Severe Energy Restriction vs Energy Restriction Alone 
 Placebo Group GH treated Group 
 Baseline After 4 
Weeks 
P value Baseline After 4 
weeks 
P value 
Body Weight 
(kg)  
93.6 +/- 0.80 86.5 +/- 
0.67 
<0.05 93.0 +/- 2.64 87.0 +/- 
2.35 
<0.05 
BMI (kg/m2) 36.3 +/- 0.49 33.6 +/- 
0.61 
<0.05 35.3 +/- 0.98 33.0 +/- 
0.93 
<0.05 
Fat mass (kg)  47.02 +/- 
1.44 
42.73 +/- 
1.66 
<0.05 49.07 +/- 
2.10 
43.71 +/- 
2.42 
<0.05 
Lean mass 
(kg) 
43.83 +/- 
1.15 
40.04 +/- 
1.14 
<0.05 42.14 +/- 
1.42 
40.61 +/- 
1.29 
<0.05 
% Lean mass 
loss 
- 8.6 +/- 1.01 >0.05  3.5 +/- 1.39 <0.051 
1 P value <0.05 between groups 
Table 4 illustrates the comparison of GH as adjunct therapy to lifestyle modifications 
versus lifestyle modifications alone. The outcomes measured in this study were body fat mass, 
 lean body mass, and change in body fat mass. These outcomes were measured at the initiation of 
the study, at six months, and at nine months, using DEXA scan as a means to differentiate 
between fat mass and lean body mass. Body fat mass showed a small decrease in both the control 
group and the GH group from baseline to the 6 and 9 month periods. Lean body mass remained 
relatively the same for both groups from baseline to the 6 and 9 month periods. The most notable 
and statistically significant difference between the two groups occurred in change in body fat 
mass, where the control group showed a smaller decline of 0.68 +/- 2.37 kg from baseline to 9 
months, while the GH group showed a decline of 2.89 +/- 3.76 kg from baseline to 9 months. 
The p value between the two groups for this decline was 0.001.  
Table 4. Comparison of Low Dose GH in Addition to Lifestyle Modifications vs Lifestyle 
Modifications alone 
 
1 P value for 9 month was 0.004, while P value for baseline and 6 months was 0.0001 
2P value between groups was 0.001 
Discussion  
 The focus of this paper was to determine whether the addition of Growth Hormone to 
standard treatment regimens was an effective adjunct in the treatment of obesity. It was theorized 
 Control Group GH treated Group 
Baseline 6 months 9 months P value Baseline 6 months 9 months P value 
Body Fat 
mass (kg) 
42.0 +/- 
9.6 
40.5 +/- 
10.0 
40.7 +/- 
10.1 
Not 
reported 
37.9 +/- 
8.8  
34.5 +/- 
9 
35.2 +/- 
9.5 
0.00011 
Lean 
Body 
Mass 
(kg) 
60.5 +/- 
10.0 
61.1 +/- 
11.0 
61.4 +/- 
10.5 
Not 
reported 
62.4 +/- 
12.1 
63.5 +/- 
12.7 
61.4 +/- 
10.5 
>0.05 
Change 
in Body 
Fat mass 
(kg) 
- - -0.68 +/- 
2.37 
- - - -2.89 +/- 
3.76 
0.0012 
 that GH had an effect on fat mass loss and lean body mass retention. In all three of the studies 
cited, fat mass loss was increased, while lean body mass was retained at a higher rate. The 
degrees of these effects varied, as well as the statistical significance of the data, depending on the 
methods, type of intervention, size of the study, and length of time that the results were observed.  
There were significant limitations in all of the studies, the greatest being time period. It is well 
understood that weight loss is a long term goal which takes months and often years to 
accomplish significant results. In the Savastano study, the outcomes were measured up to 6 
months from the beginning of the study. In the Albert study, data were collected up to 9 months 
from the initiation of the study. The Tagliaferri study had the shortest duration of observation of 
only 4 weeks. Another limitation of this research is the size of the studies cited, the largest of the 
three containing only 59 participants. In that study, nearly one third of the initial participants 
dropped out before completion of the study. This is not uncommon in weight loss studies, due to 
the difficulty of maintaining the conditions set forth at the beginning of the study. In addition, the 
inclusion and exclusion criteria for studies, while important to minimize compounding variables, 
likely caused the studies to focus on a segment of the obese population that is uncommon to 
encounter in practice. Therefore, the true safety and efficacy of GH on patients with co-morbid 
conditions in addition to obesity cannot be fully understood based on these studies alone.  
Although they were not the focus of this research, the studies discussed in this paper did 
report some data that were important to note. In both the Savastano and Albert studies, subjects 
treated with GH reported improved lipid profiles versus the placebo groups without negative 
effects on insulin sensitivity or glucose tolerance. In addition, the Tagliaferri study showed a 
decline in Resting Energy Expenditure (REE) in the placebo group (from 8807 +/- 498 to 7580 
+/- 321 kJ/24hr, P<0.05) and adjusted for LBM(201.7 +/- 13.85 to 190 +/- 9.87 kJ/kg LBM/24h, 
 NS), while the rhGH treated group actually showed an increased REE (from 8367 +/- 580 to 
8903 +/- 478 kJ/24 hr, NS) and adjusted for LBM(197.9 +/- 11.76 to 219.3 +/- 9.87 kJ/kg 
LBM/24h, P<0.05).  This data supports the proposed theory that GH supports retention of LBM 
in addition to increasing energy metabolism by LBM, leading to increased metabolic energy 
consumption by the body. Although fat mass loss was not markedly increased in the rhGH group 
versus the placebo group (5.36 kg vs. 4.29 kg), the short duration of the study likely limited the 
observation of a more substantial difference in fat mass loss.  
Conclusion  
 Growth Hormone is an effective adjunct to standard regimens in the treatment of obesity. 
The addition of GH promoted fat mass loss while also contributing to lean body mass retention 
compared to the standard treatment regimens addressed in this research.  
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